Alamar Biosciences, Inc. (ALMR)
Compare with another name Open in your desk ↗
Alamar Biosciences, Inc. (ALMR) reported revenue of $29 million for Q2 FY2026, the quarter ended 30 June 2026, up 82.1% on the same quarter a year earlier. Net income was -$13 million, and diluted earnings per share $-0.22. The figures are the company's own, from the 10-Q it filed with the SEC on 11 August 2026.
Revenue$29 millionup 82.1%
Net income-$13 million
Diluted EPS$-0.22
QuarterQ2 FY2026ended 30 June 2026
Alamar Biosciences (ALMR) in brief
Alamar Biosciences had 69 million shares outstanding at the latest filed count.
Read more
At 30 June 2026 it carried $10 million of debt and $133 million of cash. At the close of 30 October 2026 the market cap of Alamar Biosciences was $2.1 billion.Ratios
From the filings
ROEn/a
ROCEn/a
Operating marginn/a
Net marginn/a
FCF marginn/a
Interest covern/a
Debt to equity0.03
Cash conversionn/a
Share count, last 12 months0.0%
Sales CAGR, 3 yearsn/a
Profit CAGR, 3 yearsn/a
EPS, TTMn/a
At the close of 30 October 2026
Price$30.59
Market cap$2.1 billion
Stock P/En/a
Price to book6.79
EV / EBITDAn/a
Dividend yieldn/a
Market cap / salesn/a
52-week high$38.23
52-week low$19.09
Price, 1 yearn/a
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Alamar Biosciences, Inc.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.ALMRgreeksoup.ai
Daily prices to 30 October 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.The public record on ALMR
| Filings | 8 in twelve months: 5 current reports (8-K), about 2 results of operations; 2 other events; 1 officer or director change; 1 charter or bylaw amendment, or fiscal year change |
| Planned insider sales | 4 Form 144 notices in twelve months, $56.4 million; latest 14 October 2026 |
| Options tape | no listed options |
| 13F holders | 87 funds reported a position for the quarter to 30 June 2026; largest Sands Capital Alternatives, LLC |
| Insider trading | 92 sales and 2 purchases on Form 4 in twelve months |
| Congress | 0 House trades disclosed in six months |
| Short interest | 2.7 million shares short, 3.14 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 2 earnings press releases, each linked |
Quarterly results, the last 4 quarters
| Q1 FY2025 | Q2 FY2025 | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|
| Revenue | 13.1 | 16.2 | 26.0 | 29.4 |
| Cost of revenue | 6.7 | 7.6 | 11.6 | 11.7 |
| Gross profit | 6.4 | 8.6 | 14.5 | 17.7 |
| Gross margin | 49% | 53% | 56% | 60% |
| R&D | 8.3 | 8.9 | 13.0 | 13.8 |
| SG&A | 6.6 | 7.6 | 13.8 | 17.4 |
| Operating income | -8.6 | -7.9 | -12.3 | -13.5 |
| Operating margin | -65% | -49% | -47% | -46% |
| Pre-tax income | -7.7 | -7.0 | -20.9 | -13.3 |
| Net income | -7.7 | -7.0 | -21.3 | -13.2 |
| Net margin | -59% | -43% | -82% | -45% |
| Diluted EPS | -$0.68 | -$0.62 | -$1.74 | -$0.22 |
| Operating cash flow | -13.1 | -11.9 | -20.3 | -11.3 |
| Capital expenditure | 0.6 | 0.8 | 0.6 | 3.6 |
| Free cash flow | -13.6 | -12.6 | -20.9 | -15.0 |
| Shares outstanding | 69m | 69m | 69m | 69m |
| Filing | 10-Q | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Questions
What is Alamar Biosciences' market cap?
The market cap of Alamar Biosciences was $2.1 billion at the close of 30 October 2026.
How much debt does Alamar Biosciences have?
At 30 June 2026 Alamar Biosciences carried $10 million of debt and $133 million of cash.
Peers: Measuring and Control Equipment
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Agilent Technologies, Inc. A | $49.3 billion | 34.42 | 19.6% | 22.2% | 8.6% | 0.54 | 0.6% |
| Waters Corp. WAT | $45.4 billion | 115.38 | 1.1% | 7.1% | 52.5% | 0.33 | n/a |
| Mettler Toledo International Inc. MTD | $36.3 billion | 37.71 | 7,062.4% | n/a | 6.9% | 164.70 | n/a |
| Illumina, Inc. ILMN | $35.7 billion | 40.64 | 28.5% | 21.2% | 5.8% | 0.57 | n/a |
| Revvity, Inc. RVTY | $17.5 billion | 74.74 | 3.3% | 12.3% | 4.1% | 0.45 | 0.2% |
| Avantor, Inc. AVTR | $10.9 billion | 32.12 | 5.8% | 7.3% | 0.9% | 0.63 | n/a |
| Bio-Rad Laboratories, Inc. BIO | $10.0 billion | 45.15 | 3.1% | 2.1% | 1.4% | 0.17 | n/a |
| 10x Genomics, Inc. TXG | $9.1 billion | n/a | -9.1% | -14.3% | -4.3% | 0.00 | n/a |
| Bruker Corp. BRKR | $8.7 billion | n/a | -3.0% | -0.9% | 1.6% | 0.76 | n/a |
| Alamar Biosciences, Inc. ALMR | $2.1 billion | n/a | n/a | n/a | n/a | 0.03 | n/a |
| Pacific Biosciences of California, Inc. PACB | $808 million | n/a | n/a | -83.5% | 2.0% | n/a | 0.0% |
| Cytek Biosciences, Inc. CTKB | $795 million | n/a | -25.0% | -21.6% | 5.4% | 0.00 | n/a |
All 49 in Measuring and Control Equipment
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. TMO | $258.2 billion | 36.76 | 12.9% | 17.9% | 8.3% | 0.76 | 0.3% |
| KLA Corp. KLAC | $205.7 billion | 39.46 | 80.6% | n/a | 15.8% | 0.88 | 0.5% |
| Danaher Corp. DHR | $163.4 billion | 38.02 | 8.1% | 20.4% | 5.5% | 0.49 | 0.6% |
| Trane Technologies plc TT | $89.8 billion | 28.97 | 34.6% | 17.9% | 10.3% | 0.46 | 1.0% |
| AMETEK Inc. AME | $55.3 billion | 35.25 | 14.0% | 25.9% | 12.7% | 0.18 | 0.5% |
| Keysight Technologies, Inc. KEYS | $52.3 billion | 42.22 | 19.2% | 20.3% | 25.5% | 0.38 | n/a |
| Agilent Technologies, Inc. A | $49.3 billion | 34.42 | 19.6% | 22.2% | 8.6% | 0.54 | 0.6% |
| Rockwell Automation, Inc. ROK | $48.5 billion | 40.89 | 34.4% | 22.7% | 11.3% | 0.93 | 1.2% |
| Roper Technologies Inc. ROP | $46.1 billion | 19.33 | 13.4% | 28.0% | 10.9% | 0.61 | 0.8% |
| Waters Corp. WAT | $45.4 billion | 115.38 | 1.1% | 7.1% | 52.5% | 0.33 | n/a |
| Teradyne, Inc. TER | $42.8 billion | 31.47 | 37.2% | 32.1% | 74.9% | 0.00 | 0.2% |
| Coherent Corp. COHR | $41.2 billion | 51.16 | 7.4% | 11.9% | 22.5% | 0.30 | n/a |
| Mettler Toledo International Inc. MTD | $36.3 billion | 37.71 | 7,062.4% | n/a | 6.9% | 164.70 | n/a |
| Illumina, Inc. ILMN | $35.7 billion | 40.64 | 28.5% | 21.2% | 5.8% | 0.57 | n/a |
| Veralto Corp. VLTO | $27.0 billion | 27.50 | 31.0% | 21.8% | 6.4% | 0.90 | 0.5% |
| Fortive Corp. FTV | $19.4 billion | 31.06 | 11.0% | 19.6% | 7.0% | 0.59 | 0.4% |
| Revvity, Inc. RVTY | $17.5 billion | 74.74 | 3.3% | 12.3% | 4.1% | 0.45 | 0.2% |
| Trimble Inc. TRMB | $15.1 billion | n/a | -2.0% | 17.0% | 5.8% | 0.29 | n/a |
| MKS Inc. MKSI | $13.6 billion | 32.18 | 14.7% | 15.7% | 16.3% | 1.32 | 0.5% |
| Avantor, Inc. AVTR | $10.9 billion | 32.12 | 5.8% | 7.3% | 0.9% | 0.63 | n/a |
| Bio-Rad Laboratories, Inc. BIO | $10.0 billion | 45.15 | 3.1% | 2.1% | 1.4% | 0.17 | n/a |
| Onto Innovation Inc. ONTO | $9.9 billion | 75.70 | 6.9% | 12.0% | 8.1% | 0.00 | n/a |
| Cognex Corp. CGNX | $9.4 billion | 54.53 | 10.7% | 21.9% | 17.1% | 0.00 | 0.6% |
| 10x Genomics, Inc. TXG | $9.1 billion | n/a | -9.1% | -14.3% | -4.3% | 0.00 | n/a |
| Bruker Corp. BRKR | $8.7 billion | n/a | -3.0% | -0.9% | 1.6% | 0.76 | n/a |
| Ralliant Corp. RAL | $7.4 billion | n/a | -80.4% | -53.3% | n/a | 0.75 | 0.3% |
| Sensata Technologies Holding plc ST | $5.9 billion | 16.11 | 12.0% | 15.1% | 4.1% | 0.78 | 1.2% |
| Vontier Corp. VNT | $4.9 billion | 14.78 | 29.2% | 18.8% | 0.9% | 1.59 | 0.3% |
| Mirion Technologies, Inc. MIR | $4.5 billion | 157.86 | 1.6% | 6.0% | 19.6% | 0.67 | n/a |
| Badger Meter Inc. BMI | $4.2 billion | 34.27 | 19.4% | 18.8% | -2.2% | 0.00 | 1.1% |
| Itron, Inc. ITRI | $4.2 billion | 15.49 | 16.5% | 13.7% | -3.6% | 0.95 | n/a |
| Cohu Inc. COHU | $2.6 billion | n/a | -2.9% | -2.4% | 34.0% | 0.38 | n/a |
| Alamar Biosciences, Inc. ALMR | $2.1 billion | n/a | n/a | n/a | n/a | 0.03 | n/a |
| Aehr Test Systems AEHR | $1.8 billion | n/a | -3.2% | -28.3% | -15.2% | 0.00 | n/a |
| Allient Inc. ALNT | $1.5 billion | 50.30 | 9.2% | 8.4% | 10.6% | 0.56 | 0.2% |
| Pacific Biosciences of California, Inc. PACB | $808 million | n/a | n/a | -83.5% | 2.0% | n/a | 0.0% |
| Transcat Inc. TRNS | $808 million | n/a | n/a | n/a | n/a | 0.36 | n/a |
| Cytek Biosciences, Inc. CTKB | $795 million | n/a | -25.0% | -21.6% | 5.4% | 0.00 | n/a |
| Frequency Electronics Inc. FEIM | $744 million | 271.48 | 2.2% | 2.5% | 6.3% | 0.00 | n/a |
| Mesa Laboratories Inc. MLAB | $716 million | 152.23 | 2.5% | 9.0% | 3.0% | 0.76 | 0.5% |
| Senseonics Holdings, Inc. SENS | $504 million | n/a | -121.1% | -223.2% | 90.6% | 0.62 | n/a |
| 908 Devices Inc. MASS | $427 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Nautilus Biotechnology, Inc. NAUT | $349 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Quantum-Si Inc. QSI | $317 million | n/a | -54.7% | -6,887.8% | -53.0% | 0.00 | n/a |
| Intest Corp. INTT | $184 million | 119.38 | 0.9% | 0.5% | 5.4% | 0.06 | n/a |
| Hurco Companies Inc. HURC | $143 million | n/a | -3.4% | -2.8% | -1.9% | n/a | n/a |
| Kewaunee Scientific Corp. KEQU | $95 million | 11.94 | 11.0% | 5.4% | 5.3% | 0.25 | n/a |
| Seer, Inc. SEER | $93 million | n/a | -30.1% | -498.2% | -12.7% | 0.00 | 0.0% |
| Rapid Micro Biosystems, Inc. RPID | $37 million | n/a | -288.5% | -141.5% | 16.1% | 1.08 | n/a |
15 companies share its SEC industry code (Laboratory Analytical Instruments); the rest are the names nearest in size in its wider industry, Measuring and Control Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.